Systems molecular imaging: Right around the corner

Nano Biomedicine and Engineering

Volumn 6, Issue 1, 2014, Pages 1-5

  Shen, Baozhong ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Multifunctional nanoprobes; Multimodality imaging; System molecular imaging; Targeted imaging; Theranostics

Indexed keywords

MAGNETIC NANOPARTICLE;

BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; CELL ORGANELLE; DRUG DEVELOPMENT; HUMAN; MOLECULAR IMAGING; REVIEW; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; TUMOR DIAGNOSIS;

EID: 84897975273     PISSN: None     EISSN: 21505578     Source Type: Journal    
DOI: 10.5101/nbe.v6i1.p1-6     Document Type: Review

References (45)

1. Weissleder R: Molecular imaging: exploring the next frontier. Radiology 1999, 212(3): 609-614.
2. Shen B: Molecular Imaging. Beijing: People's Health Publishing House (First Edition) 2007.
3. Brazma A, Krestyaninova M, Sarkans U: Standards for systems biology. Nature reviews Genetics 2006, 7(8): 593-605.
4. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P et al.: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. The New England journal of medicine 2012, 366(10): 883-892.
5. Quail DF, Joyce JA: Microenvironmental regulation of tumor progression and metastasis. Nature medicine 2013, 19(11): 1423-1437.
6. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144(5): 646-674.
7. Bedard PL, Hansen AR, Ratain MJ, Siu LL: Tumour heterogeneity in the clinic. Nature 2013, 501(7467): 355-364.
8. Marte B: Tumour heterogeneity. Nature 2013, 501(7467): 327.
9. Meacham CE, Morrison SJ: Tumour heterogeneity and cancer cell plasticity. Nature 2013, 501(7467): 328-337.
10. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong AS et al.: Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013, 497(7447): 108-112.
11. Sawyers CL: The cancer biomarker problem. Nature 2008, 452(7187): 548-552.
12. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM et al.: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-smallcell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. The lancet oncology 2012, 13(3): 239-246.
13. Hynes NE, Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nature reviews Cancer 2005, 5(5): 341-354.
14. Roda JM, Sumner LA, Evans R, Phillips GS, Marsh CB, Eubank TD: Hypoxia-inducible factor-2alpha regulates GM-CSF-derived soluble vascular endothelial growth factor receptor 1 production from macrophages and inhibits tumor growth and angiogenesis. J Immunol 2011, 187(4): 1970-1976.
15. Ho QT, Kuo CJ: Vascular endothelial growth factor: biology and therapeutic applications. The international journal of biochemistry&cell biology 2007, 39(7-8): 1349-1357.
16. Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocrine reviews 2004, 25(4): 581-611.
17. Semenza GL: Targeting HIF-1 for cancer therapy. Nature reviews Cancer 2003, 3(10): 721-732.
18. Zhang L, Wang K, Zhao F, Hu W, Chen J, Lanza GM, Shen B, Zhang B: Near Infrared Imaging of EGFR of Oral Squamous Cell Carcinoma in Mice Administered Arsenic Trioxide. PloS one 2012, 7(9): e46255.
19. Wang K, Wang K, Li W, Huang T, Li R, Wang D, Shen B, Chen X: Characterizing breast cancer xenograft epidermal growth factor receptor expression by using near-infrared optical imaging. Acta Radiol 2009, 50(10): 1095-1103.
20. Ke S, Wen X, Gurfinkel M, Charnsangavej C, Wallace S, Sevick-Muraca EM, Li C: Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. Cancer Res 2003, 63: 7870-7875.
21. Hirata M, Kanai Y, Naka S, Yoshimoto M, Kagawa S, Matsumuro K, Katsuma H, Yamaguchi H, Magata Y, Ohmomo Y: A useful EGFR-TK ligand for tumor diagnosis with SPECT: development of radioiodinated 6-(3-morpholinopropoxy)-7-ethoxy-4-(3'-iodophenoxy) quinazoline. Annals of nuclear medicine 2013, 27(5): 431-443.
22. Yeh HH, Ogawa K, Balatoni J, Mukhapadhyay U, Pal A, Gonzalez-Lepera C, Shavrin A, Soghomonyan S, Flores L, 2nd, Young D et al.: Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT. Proceedings of the National Academy of Sciences of the United States of America 2011, 108(4): 1603-1608.
23. Fu P, Shen B, Zhao C, Tian G: Molecular imaging of MDM2 messenger RNA with 99mTc-labeled antisense oligonucleotides in experimental human breast cancer xenografts. J Nucl Med 2010, 51(11): 1805-1812.
24. Zhao D, Tu Y, Wan L, Bu L, Huang T, Sun X, Wang K, Shen B: In Vivo Monitoring of Angiogenesis Inhibition via Down-Regulation of Mir-21 in a VEGFR2-Luc Murine Breast Cancer Model Using Bioluminescent Imaging. PLoS One 2013, 8(8): e71472.
25. Huang T, Civelek AC, Li J, Jiang H, Ng CK, Postel GC, Shen B, Li XF: Tumor microenvironment-dependent 18F-FDG, 18F-fluorothymidine, and 18F-misonidazole uptake: a pilot study in mouse models of human nonsmall cell lung cancer. J Nucl Med 2012, 53(8): 1262-1268.
26. Gao J, Chen K, Miao Z, Ren G, Chen X, Gambhir SS, Cheng Z: Affibody-based nanoprobes for HER2-expressing cell and tumor imaging. Biomaterials 2011, 32(8): 2141-2148.
27. Capala J, Bouchelouche K: Molecular imaging of HER2-positive breast cancer: a step toward an individualized 'image and treat' strategy. Current opinion in oncology 2010, 22(6): 559-566.
28. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC: Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med 1998, 4(5): 623-626.
29. Schmieder AH, Winter PM, Williams TA, Allen JS, Hu G, Zhang H, Caruthers SD, Wickline SA, Lanza GM: Molecular MR Imaging of Neovascular Progression in the Vx2 Tumor with alphavbeta3-Targeted Paramagnetic Nanoparticles. Radiology 2013, 268(2): 470-480.
30. Schmieder AH, Wang K, Zhang H, Senpan A, Pan D, Keupp J, Caruthers SD, Wickline SA, Shen B, Wagner EM et al.: Characterization of early neovascular response to acute lung ischemia using simultaneous F/H MR molecular imaging. Angiogenesis 2013.
31. Sun X, Yan Y, Liu S, Cao Q, Yang M, Neamati N, Shen B, Niu G, Chen X: 18F-FPPRGD2 and 18F-FDG PET of Response to Abraxane Therapy. J Nucl Med 2011, 52(1): 140-146.
32. Weissleder R, Pittet MJ: Imaging in the era of molecular oncology. Nature 2008, 452(7187): 580-589.
33. Kinahan PE, Townsend DW, Beyer T, Sashin D: Attenuation correction for a combined 3D PET/CT scanner. Medical physics 1998, 25(10): 2046-2053.
34. Medarova Z, Pham W, Farrar C, Petkova V, Moore A: In vivo imaging of siRNA delivery and silencing in tumors. Nature medicine 2007, 13(3): 372-377.
35. Lee H, Yu MK, Park S, Moon S, Min JJ, Jeong YY, Kang HW, Jon S: Thermally cross-linked superparamagnetic iron oxide nanoparticles: synthesis and application as a dual imaging probe for cancer in vivo. Journal of the American Chemical Society 2007, 129(42): 12739-12745.
36. Foy SP, Manthe RL, Foy ST, Dimitrijevic S, Krishnamurthy N, Labhasetwar V: Optical imaging and magnetic field targeting of magnetic nanoparticles in tumors. ACS nano 2010, 4(9): 5217-5224.
37. Xie J, Chen K, Huang J, Lee S, Wang J, Gao J, Li X, Chen X: PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials 2010, 31(11): 3016-3022.
38. Stelter L, Pinkernelle JG, Michel R, Schwartlander R, Raschzok N, Morgul MH, Koch M, Denecke T, Ruf J, Baumler H et al.: Modification of aminosilanized superparamagnetic nanoparticles: feasibility of multimodal detection using 3T MRI, small animal PET, and fluorescence imaging. Molecular imaging and biology: MIB: the official publication of the Academy of Molecular Imaging 2010, 12(1): 25-34.
39. Scheffler M, Kobe C, Zander T, Nogova L, Kahraman D, Thomas R, Neumaier B, Dietlein M, Wolf J: Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated nonsmall cell lung cancer (NSCLC) using sequential [18F] fluorothymidine (FLT-)PET. Lung Cancer 2012, 77(3): 617-620.
40. Shen B: Molecular Imaging. Beijing: People's Health Publishing House (Second Edition) 2010.
41. Lanza GM, Moonen C, Baker JR, Jr., Chang E, Cheng Z, Grodzinski P, Ferrara K, Hynynen K, Kelloff G, Lee YE et al.: Assessing the barriers to image-guided drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2014, 6(1): 1-14.
42. Horcajada P, Chalati T, Serre C, Gillet B, Sebrie C, Baati T, Eubank JF, Heurtaux D, Clayette P, Kreuz C et al.: Porous metal-organic-framework nanoscale carriers as a potential platform for drug delivery and imaging. Nature materials 2010, 9(2): 172-178.
43. Shen B: Molecular Imaging: Principle and Practice. Beijing: People's Health Publishing House 2013.
44. Palekar-Shanbhag P, Jog SV, Chogale MM, Gaikwad SS: Theranostics for cancer therapy. Current drug delivery 2013, 10(3): 357-362.
45. Pan D, Sanyal N, Schmieder AH, Senpan A, Kim B, Yang X, Hu G, Allen JS, Gross RW, Wickline SA et al.: Antiangiogenic nanotherapy with lipase-labile Sn-2 fumagillin prodrug. Nanomedicine 2012, 7(10): 1507-1519.